Your Doctor Discussion Guide

If you are considering CRYSVITA® (burosumab-twza), you may have questions. Take this guide to your next appointment to help start the conversation. Together, you and your doctor can decide if CRYSVITA is right for you.

What is CRYSVITA?

CRYSVITA is a prescription medicine used to treat adults and children 6 months of age and older with X-linked hypophosphatemia (XLH).

Important Safety Information

You should not take CRYSVITA if:

- You take an oral phosphate supplement and/or a specific form of vitamin D supplement (such as calcitriol, paricalcitol, doxercalciferol, calcifediol).
- Your phosphorus levels from a blood sample are within or above the normal range for age.
- You have kidney problems.

Please see Important Safety Information continued throughout this guide.
Please see the full Prescribing Information for CRYSVITA here.

About CRYSVITA

What is CRYSVITA and how is it different from other treatments?

Can you tell me about how CRYSVITA was studied? What does it mean for me?

What are the possible side effects?

How is CRYSVITA given, and how often will I need treatment?

How long does it take before CRYSVITA starts to work?

Is CRYSVITA right for me?

Accessing CRYSVITA treatment

Will insurance cover CRYSVITA? What do I need to do to start the process?

Are there any financial support programs available for CRYSVITA?

Resources and social support

What resources are available to help support people who are taking CRYSVITA?

Important Safety Information

What is the most important information you should know about CRYSVITA?

- Some patients developed allergic reactions (e.g., rash and hives) while taking CRYSVITA. Your doctor will monitor you for symptoms of an allergic reaction while you are taking CRYSVITA. Your treatment may need to be discontinued for serious allergic reactions.
- High levels of phosphorus in the blood have been reported in some patients taking CRYSVITA. This may be related to a risk of high calcium levels in the kidneys. Your doctor will collect blood samples to monitor your levels. If you are already taking CRYSVITA, dose interruption and/or dose reduction may be required based on your serum phosphorus levels.

Please see Important Safety Information continued throughout this guide.
Please see the full Prescribing Information for CRYSVITA here.

CRYSVITA®
burosumab-twza
Injection 10, 20, 30 mg/mL

Important Safety Information

What is the most important information you should know about CRYSVITA? (cont'd)

- High levels of calcium in the blood have been reported in patients taking CRYSVITA. The risk is greater in patients with pre-existing hyperparathyroidism (overactive parathyroid glands), for those who are unable to move for extended periods of time, become dehydrated, have high vitamin D levels, or have kidney issues. If you are at greater risk, your doctor will monitor your blood calcium and parathyroid hormone levels before you start and while taking CRYSVITA. If you develop high levels of blood calcium, your doctor may need to stop your treatment until it is adequately managed.
- Administration of CRYSVITA may result in reactions at the injection site, such as hives, reddening of the skin, rash, swelling, bruising, pain, severe itching of the skin, and collection of blood outside of a blood vessel (i.e., hematoma). Call your doctor if you develop an injection site reaction. CRYSVITA may be discontinued if severe injection site reactions occur.

What are the possible side effects of CRYSVITA?

- Adverse reactions that were seen in children with XLH are:
  - Fever
  - Injection site reaction
  - Cough
  - Vomiting
  - Pain in arms and legs
  - Headache
  - Tooth abscess
  - Dental cavities
  - Diarrhea
  - Decreased vitamin D levels
  - Toothache
  - Constipation
  - Muscle pain
  - Rash
  - Dizziness
  - Nausea
- Adverse reactions that were seen in adults with XLH are:
  - Back pain
  - Headache
  - Tooth infection
  - Restless legs syndrome
  - Decreased vitamin D levels
  - Dizziness
  - Constipation
  - Muscle spasms
  - Phosphorus levels increased in the blood
- Narrowing of the spaces within the spine is common in adults with XLH, and pressure on the spinal cord has been reported in adults taking CRYSVITA. It is not known if taking CRYSVITA worsens the narrowing of the spaces within the spine or the pressure on the spinal cord.

Before taking CRYSVITA, tell your doctor about all of your medications (including supplements) and medical conditions, including if you:

- Are taking oral phosphate and/or active vitamin D (such as calcitriol, paricalcitol, doxercalciferol, calcifediol).
- Are pregnant, think you may be pregnant, or plan to become pregnant. There is not enough experience to know if CRYSVITA may harm your unborn baby. Report pregnancies to the Kyowa Kirin, Inc. Adverse Event reporting line at 1-844-768-3544.
- Are breastfeeding or plan to breastfeed. There is not enough experience to know if CRYSVITA passes into your breast milk. Talk with your doctor about the best way to feed your baby while you receive CRYSVITA.

While taking CRYSVITA, tell your doctor if you experience:

- An allergic reaction such as rash or hives
- A rash, swelling, bruising, or other reaction at the injection site
- New or worsening restless legs syndrome

These are not all the possible side effects of CRYSVITA. Call your doctor for medical advice about side effects.

You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Kyowa Kirin, Inc. at 1-844-768-3544.

For important risk and use information, please see the full Prescribing Information for CRYSVITA here.

KYOWA KIRIN

CRYSVITA® burosumab-twza injection 10, 20, 30 mg/mL

COMM-US-CRY-1061 September 2025